Last reviewed · How we verify

metoprolol plus morphine — Competitive Intelligence Brief

metoprolol plus morphine (metoprolol plus morphine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker plus opioid analgesic combination. Area: Cardiovascular; Pain management.

marketed Beta-blocker plus opioid analgesic combination Beta-1 adrenergic receptor; mu-opioid receptor Cardiovascular; Pain management Small molecule Live · refreshed every 30 min

Target snapshot

metoprolol plus morphine (metoprolol plus morphine) — Sahlgrenska University Hospital. Metoprolol reduces heart rate and blood pressure via beta-1 adrenergic blockade, while morphine provides analgesia and reduces anxiety through opioid receptor agonism and sympathetic nervous system depression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
metoprolol plus morphine TARGET metoprolol plus morphine Sahlgrenska University Hospital marketed Beta-blocker plus opioid analgesic combination Beta-1 adrenergic receptor; mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker plus opioid analgesic combination class)

  1. Sahlgrenska University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metoprolol plus morphine — Competitive Intelligence Brief. https://druglandscape.com/ci/metoprolol-plus-morphine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: